Farhad Ravandi, MD, PhD from the MD Anderson Cancer Center, Houston, USA is commenting on the abstract PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML)
Reference: EHA Library. Bose P. Jun 14, 2019; 266472
